CORBUS PHARMACEUTICALS HOLDI
CRBPNASDAQπ #4252 by market capEarnings Mar 8 Β· PostUS Equity
ββ
Quote unavailableTrack CRBP
Get earnings, price moves & breaking news on Telegram
24hβ
7dβ
14dβ
30dβ
ytdβ
1yβ
π¦Market Cap
$42M
Small Cap
πRevenue Growth (YoY)
0.0%
Slowing
πGross Margin
0.0%
Thin
π΅FCF Margin
0.0%
Thin
βοΈP/S Ratio
0.0x
Cheap
Otter Score
β
Insufficient data
No chart data available for CRBP.
Trading Snapshot
- Day Range
- β
- 52-Week Range
- $2.01 β $12.88
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 20.6M
- Next Earnings
- 2027-03-08
Fundamentals Snapshot
- Annual Revenue
- β
- Last Q Revenue
- β
- P/E Ratio
- -0.3
- P/S Ratio
- 0.0x
- EPS (TTM)
- $-5.58
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +9.3%
CORBUS PHARMACEUTICALS HOLDI
CRBPFinancial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isnβt profitable yet.
β$85Mβ² +75.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
β$64Mβ² +54.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing ownerβs slice.
13.3Mβ² +9.3% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$27Mβ² +$13M YoY
About CORBUS PHARMACEUTICALS HOLDI
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFΓ expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
π¦¦
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Insufficient data for all five components.
πQualityβ
β
β
β
β
πGrowthβ
β
β
β
β
βοΈValuationβ
β
β
β
β
π§Dilutionβ
β
β
β
β
Overall Score
Insufficient data
β/100
Analyst data unavailable.
Latest News & Updates
News unavailable.